- Home
- CATX vs CRMD Comparison
CATX vs CRMD Comparison
Compare CATX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | CRMD |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.6M | 509.9M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CATX | CRMD |
|---|---|---|
| Price | $4.42 | $7.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $12.11 | ★ $14.67 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $12.71 | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.33 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $1.60 | $5.60 |
| 52 Week High | $6.16 | $17.43 |
Technical Indicators
Market Signals| Indicator | CATX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 55.64 |
| Support Level | $3.24 | $6.14 |
| Resistance Level | $4.54 | $7.44 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 34.92 | 97.18 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.